Fig 2: Nomogram to display the prognosis value of FAM50A in CRC.(A-E) represent the results of prognostic proportional risk analysis in T, N, M and TNM stages and FM50A expression. (F) Nomogram constructed with different variables. (G) Calibration curve of nomogram.

Fig 3: Cox regression analysis in CRC.(A) Overall survival rate in CRC patients (n = 145). (B) OS in female and male groups. (C) OS in different age groups. (D) OS related to tumor size. (E) OS related to tumor location. (F) OS of ddifferent cancer sites. (G) OS interrelated with differentiation. (H-K) OS in T, N, M and TNM stages. (L) OS in FAM50A high and low groups. * P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ns: no significance.

Fig 4: Correlation of FAM50A expression with clinical and pathological features of CRC.(A) Expression of FAM50A in normal and cancer tissues. (B) ROC curve analysis identified the different expression between the two groups. (C) Expression of FAM50A in male and female patients with CRC. (D) Expression of FAM50A in different age groups. (E) Expression of FAM50A in relation to tumor size. (F) Expression of FAM50A in relation to tumor location. (G) FAM50A expression in relation to cancer site. (H) FAM50A expression in relation to histological differentiation (M, moderate differentiation; P, poor differentiation). (I) FAM50A expression in relation to the depth of tumor invasion. (J) FAM50A expression according to lymph node metastasis. (K) FAM50A expression according to the presence of distant metastasis. (L) FAM50A expression according to TNM stage. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, ns: not significant.

Fig 5: Knocking down FAM50A leads to S phase arrest in CRC cells.(A-B) Cell cycle assays were performed on SW480 and HCT-8 cells after FAM50A was knocked down (up: SW480, down: HCT-8). (C-D) Western blot assays were conducted to detect the expression of cell cycle and cell cycle-related proteins in CRC cells.